Search results
Showing 136 to 150 of 559 results for oral care
Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)
This guideline covers the assessment, preparation, training and monitoring needed when using sedation in people aged under 19. It aims to help healthcare professionals decide when sedation is the most clinically and cost effective option for reducing pain and anxiety during operations for children and young people.
This indicator covers tooth extractions due to decay for children admitted as inpatients to hospital, aged 10 years and under. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Oesophago-gastric cancer: assessment and management in adults (NG83)
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support. It aims to reduce variation in practice through better organisation of care and support, and improve quality of life and survival by giving advice on the most suitable treatments depending on cancer type, stage and location.
Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)
This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.
This quality standard covers diagnosing, assessing and managing food allergy in children and young people (under 19) and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS118Show all sections
Sections for QS118
- Quality statements
- Quality statement 1: Allergy-focused clinical history
- Quality statement 2: Diagnosing IgE-mediated food allergy
- Quality statement 3: Diagnosing non-IgE-mediated food allergy
- Quality statement 4: Referral to secondary or specialist care
- Quality statement 5 (placeholder): Diagnosing food allergy in adults
- Quality statement 6 (placeholder): Nutritional support for food allergy
- Update information
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer ID6406
In development Reference number: GID-TA11341 Expected publication date: 02 December 2026
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
This guideline covers the diagnosis and management of gout. It includes recommendations on diagnosing gout, managing flares, long-term management of gout and referral to specialist services.
Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults.
The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies (MIB24)
NICE has developed a medtech innovation briefing (MIB) on the OraQuick HCV point-of-care test for rapid detection of hepatitis C virus antibodies
Evidence-based recommendations on cabotegravir (Vocabria) with rilpivirine (Rekambys) for treating HIV-1 in adults. This includes adults with virological suppression (HIV-1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen, and without any evidence of viral resistance to, and no previous virological failure with, any non-nucleoside reverse transcriptase inhibitors or integrase inhibitors.
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)
Evidence-based recommendations on cetuximab (Erbitux) for treating recurrent or metastatic squamous cell cancer of the head and neck in adults.
Managing medicines for adults receiving social care in the community (NG67)
This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.
Summary of the evidence on topical timolol for treating infantile haemangioma (strawberry marks) to inform local NHS planning and decision-making
This guideline covers the care of women with a singleton pregnancy at increased risk of, or with symptoms and signs of, preterm labour (before 37 weeks), and women with a singleton pregnancy having a planned preterm birth. It aims to reduce the risks of preterm birth for the baby and describes treatments to prevent or delay early labour and birth.